International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
| العنوان: | International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis |
|---|---|
| المؤلفون: | Cem Akin, Karin Hartmann, Andreas Reiter, Peter Valent, Srdan Verstovsek, Dean D. Metcalfe, Knut Brockow, Wolfgang R. Sperr, Daniel J. DeAngelo, Jason Gotlib, Luis Escribano, Animesh Pardanani, Olivier Hermine, Michel Arock, Alberto Orfao, Lawrence B. Schwartz, Hanneke C. Kluin-Nelemans, Hans-Peter Horny, Karl Sotlar, Ayalew Tefferi, Tracy I. George |
| المساهمون: | Faculteit Medische Wetenschappen/UMCG, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL) |
| المصدر: | Blood, 121(13), 2393-2401. AMER SOC HEMATOLOGY |
| بيانات النشر: | AMER SOC HEMATOLOGY, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Consensus, Organ Dysfunction Scores, International Cooperation, medicine.medical_treatment, Immunology, IMATINIB MESYLATE, Alpha interferon, Disease, ACUTE MYELOID-LEUKEMIA, Community Networks, Biochemistry, Myeloid Neoplasm, Targeted therapy, Mastocytosis, Systemic, Internal medicine, Humans, Medicine, MAST-CELL LEUKEMIA, Systemic mastocytosis, Societies, Medical, CLADRIBINE, Clinical Trials as Topic, business.industry, Cell Biology, Hematology, C-KIT MUTATION, medicine.disease, Mast cell leukemia, Hematologic Diseases, Europe, Clinical trial, Imatinib mesylate, OF-THE-LITERATURE, Disease Progression, SPANISH NETWORK, Clinical Competence, INTERFERON-ALPHA, business, TYROSINE KINASE INHIBITOR, PHASE-II TRIAL, Mastocytosis, Perspectives |
| الوصف: | Systemic mastocytosis (SM) is characterized by accumulation of neoplastic mast cells and is classified into indolent and aggressive forms. The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced features. These variants, henceforth collectively referred to as advanced SM for the purposes of this report, are typically characterized by organ damage and shortened survival duration. In contrast to indolent SM, in which symptoms are usually managed by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control in advanced SM. Unfortunately, current drug treatment of these patients rarely results in complete clinical and histopathologic remissions or improved survival time. Previously defined response criteria were adapted to the heterogeneous presentations of advanced SM and the limited effects of available drugs. However, recent advances in understanding the molecular pathogenesis of SM and the corresponding prospect in targeted therapy make it a priority to modify these criteria. Our current study is the product of an international group of experts and summarizes the challenges in accomplishing this task and forwards a new proposal for response criteria, which builds on prior proposals and should facilitate response evaluation in clinical trials. |
| اللغة: | English |
| تدمد: | 1528-0020 0006-4971 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c971dbbebebb4b9cd00b965a416f253aTest https://doi.org/10.1182/blood-2012-09-458521Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c971dbbebebb4b9cd00b965a416f253a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|